Karyopharm announces new preliminary data in overall survival (os) in selinexor-treated patients with advanced or recurrent tp53 wild-type endometrial cancer as part of pre-specified exploratory subgroup analysis of the siendo study

Long-term safety and efficacy data from siendo study in the tp53 wild-type exploratory subgroup showed signals of improvement in overall survival  (os) regardless of mismatched repair status (mmr) median os not reached for selinexor-treated patients who are tp53 wild-type pmmr newton, mass., nov. 6, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated long-term safety and efficacy data from a pre-specified exploratory subgroup analysis of the siendo study (nct03555422) in patients with advanced or recurrent tp53 wild-type endometrial cancer at the international gynecological cancer society (igcs) annual global meeting in seoul, south korea.
KPTI Ratings Summary
KPTI Quant Ranking